TY - JOUR T1 - Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. AU - Mori,Takehiko, AU - Aisa,Yoshinobu, AU - Watanabe,Reiko, AU - Yamazaki,Rie, AU - Kato,Jun, AU - Shimizu,Takayuki, AU - Shigematsu,Naoyuki, AU - Kubo,Atsushi, AU - Yajima,Tomonaru, AU - Hibi,Toshifumi, AU - Ikeda,Yasuo, AU - Okamoto,Shinichiro, PY - 2008/01/14/received PY - 2008/03/18/accepted PY - 2008/5/21/pubmed PY - 2008/8/20/medline PY - 2008/5/21/entrez SP - 651 EP - 7 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 14 IS - 6 N2 - We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML). The conditioning regimen consisted of 12 Gy of TBI followed by high-dose cytarabine (3 g/m(2)) every 12 hours for 4 days in combination with the continuous administration of G-CSF. Stem cell sources included bone marrow or peripheral blood stem cells (PBSC) from human leukocyte antigen (HLA)-identical siblings (n = 24), or bone marrow from HLA serologically matched unrelated donors (n = 26). Fifty patients (median age, 38 years) were evaluated. At HSCT, 35 patients were in the first or second complete remission (CR1/2), and 15 patients were not in remission (n = 14) or in the third CR (n = 1). Thirty-six of 50 patients are currently alive, with a median follow-up period of 5.6 years (range: 1.1-12.1 years). The 5-year estimated overall survival (OS) and disease-free survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 82.1% (95% CI, 69.0%-95.2%) in patients with AML in the first or second CR, 46.7% (95% CI, 21.4%-72.0%), and 40.0% (95% CI, 15.3%-64.7%) in patients with AML in other stages. The 2-year cumulative incidence of treatment-related mortality (TRM) of all patients was 10.4% (95% CI, 1.8%-18.6%). The only factors affecting the OS and DFS were disease status at transplant and cytogenetics by multivariate analysis. These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for allogeneic HSCT for AML, providing a high DFS and low TRM. SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/18489990/Long_term_follow_up_of_allogeneic_hematopoietic_stem_cell_transplantation_for_de_novo_acute_myelogenous_leukemia_with_a_conditioning_regimen_of_total_body_irradiation_and_granulocyte_colony_stimulating_factor_combined_high_dose_cytarabine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083-8791(08)00115-8 DB - PRIME DP - Unbound Medicine ER -